Amylin Pharma (AMLN) Posts Wider than Expected Q2 Loss; Revs Beat
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Financial Fact:
Net loss per share, basic and diluted: -0.66
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Net loss per share, basic and diluted: -0.66
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Amylin Pharma (NASDAQ: AMLN) reported Q2 loss of ($0.21), $0.03 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $158.07 million versus the consensus estimate of $157.72 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
- Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
